CIPLA - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.7
| Stock Code | CIPLA | Market Cap | 1,09,346 Cr. | Current Price | 1,354 ₹ | High / Low | 1,673 ₹ |
| Stock P/E | 31.8 | Book Value | 423 ₹ | Dividend Yield | 0.96 % | ROCE | 13.7 % |
| ROE | 10.4 % | Face Value | 2.00 ₹ | DMA 50 | 1,357 ₹ | DMA 200 | 1,395 ₹ |
| Chg in FII Hold | -1.38 % | Chg in DII Hold | 1.26 % | PAT Qtr | 385 Cr. | PAT Prev Qtr | 822 Cr. |
| RSI | 43.6 | MACD | 1.09 | Volume | 15,42,727 | Avg Vol 1Wk | 14,04,324 |
| Low price | 1,166 ₹ | High price | 1,673 ₹ | PEG Ratio | 3.04 | Debt to equity | 0.00 |
| 52w Index | 37.1 % | Qtr Profit Var | -69.1 % | EPS | 43.5 ₹ | Industry PE | 32.5 |
CIPLA shows moderate potential for swing trading. The current price of ₹1,354 is near its 50 DMA (₹1,357) and slightly below its 200 DMA (₹1,395), indicating consolidation. RSI at 43.6 suggests neutral momentum, while MACD at 1.09 reflects mild bullish sentiment. The company is debt-free and has strong fundamentals with EPS of ₹43.5 and book value of ₹423. However, quarterly PAT dropped sharply (-69.1%), and valuations are slightly stretched with a P/E of 31.8 compared to industry P/E of 32.5. The PEG ratio of 3.04 also highlights overvaluation relative to growth.
✅ Optimal Entry Price: ₹1,320–₹1,340 (closer to support levels)
📈 Exit Strategy (if already holding): Consider booking profits near ₹1,420–₹1,450 unless momentum strengthens beyond resistance.
🌟 Positive
- 📈 Debt-free balance sheet ensures financial stability.
- 💹 EPS of ₹43.5 reflects strong earnings power.
- 📊 Book value of ₹423 provides valuation support.
- 📈 Increase in DII holding (+1.26%) highlights domestic institutional confidence.
⚠️ Limitation
- 📉 Quarterly PAT declined significantly (₹822 Cr. → ₹385 Cr., down 69.1%).
- 📊 PEG ratio of 3.04 suggests overvaluation relative to growth.
- 📉 ROCE at 13.7% and ROE at 10.4% are modest compared to peers.
- 💸 Dividend yield of 0.96% is moderate but not highly attractive.
📰 Company Negative News
- 📉 Decline in FII holding (-1.38%) shows reduced foreign investor confidence.
- 📉 Sharp fall in quarterly profits raises caution.
📰 Company Positive News
- 📈 Increase in DII holding (+1.26%) highlights domestic institutional support.
- 💹 Debt-free status adds financial strength.
🏭 Industry
- 📊 Industry P/E at 32.5 is close to CIPLA’s 31.8, suggesting fair valuation.
- 🏥 Pharmaceutical sector benefits from long-term healthcare demand but faces regulatory and margin pressures.
✅ Conclusion
CIPLA is a fair swing trade candidate with strong fundamentals and debt-free status, but declining profits and stretched valuations limit upside. Entry around ₹1,320–₹1,340 is safer, while profit booking near ₹1,420–₹1,450 is advisable if already holding. Caution is warranted due to weak quarterly performance and reduced foreign investor confidence.
Would you like me to also compare CIPLA’s swing trade outlook with peers like Sun Pharma or Dr. Reddy’s to highlight relative opportunities in the pharma sector?